Document Detail

Population pharmacokinetic-pharmacodynamic analysis of neutropenia in cancer patients receiving PM00104 (Zalypsis(®)).
MedLine Citation:
PMID:  23055348     Owner:  NLM     Status:  MEDLINE    
BACKGROUND AND OBJECTIVE: PM00104 (Zalypsis(®)) is a novel marine-derived compound that has shown antineoplastic activity against a number of human tumour cell lines. Myelosuppression was found to be a PM00104 dose-limiting toxicity during phase I studies. The objective of this study was to characterize the time course of neutropenia after intravenous PM00104 administration in cancer patients.
METHODS: Absolute neutrophil counts (ANCs) and pharmacokinetic data from 144 patients receiving PM00104 doses ranging from 0.053 to 5 mg/m(2) were used to estimate the system-related (baseline ANC [Circ(0)], mean transit time [MTT], feedback on proliferation [γ] and maturation [δ]) and drug-specific (first-order elimination rate constant from effect compartment [k(e0)] [α and β]) parameters of a modified Friberg's model. The concentrations in the effect compartment (C(e)) were assumed to reduce the proliferation rate of the progenitor cells according to the function [Formula: see text] Model evaluation and simulations were undertaken to evaluate the effect of dose intensity, dose density and the intravenous infusion duration on severe neutropenia incidence.
RESULTS: The typical values (between-subject variability [%]) of the Circ(0), MTT, γ, δ, k(e0), α and β were estimated to be 5.66 × 10(9) cells/L (13 %), 149 h (29 %), 0.136, 0.191, 0.00639 h(-1) (32 %), 0.332 L/µg (24 %) and 1.47, respectively. Age, bodyweight, sex, serum albumin, total protein, liver metastases, number of previous chemotherapy lines and performance status were not associated with model parameters. The model evaluation evidenced an accurate prediction of the neutropenia grade 3 and/or 4 incidence. Simulations indicated that PM00104 dose and dosing interval, but not infusion duration, were the main determinants of the neutropenia severity and duration.
CONCLUSIONS: The time course of neutropenia following PM00104 was well characterized by the model developed. The model-predicted time course of the ANCs and its variability confirmed that neutropenia is reversible, of short duration and non-cumulative.
Mario González-Sales; Belén Valenzuela; Carlos Pérez-Ruixo; Carlos Fernández Teruel; Bernardo Miguel-Lillo; Arturo Soto-Matos; Juan Jose Pérez-Ruixo
Related Documents :
24342458 - The effect of gradual increment in rhg-csf dose on stem cell yields in patients with mu...
7999598 - Erythemal and therapeutic response of psoriasis to puva using high-dose uva.
15046958 - In vitro dermal disposition of abamectin (avermectin b(1)) in livestock.
18766628 - The induction of delayed type hypersensitivity to dinitrochlorobenzene in the chicken.
24252908 - Membrane signaling induced by high doses of ionizing radiation in the endothelial compa...
8931298 - Treatment and control of psoroptic mange (sheep scab) with moxidectin.
Publication Detail:
Type:  Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical pharmacokinetics     Volume:  51     ISSN:  0312-5963     ISO Abbreviation:  Clin Pharmacokinet     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-12-10     Completed Date:  2013-05-21     Revised Date:  2013-05-24    
Medline Journal Info:
Nlm Unique ID:  7606849     Medline TA:  Clin Pharmacokinet     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  751-64     Citation Subset:  IM    
Consulting Projects for Research, Picayo, 3 Puzol, 46530, Valencia, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / administration & dosage*,  pharmacokinetics
Dose-Response Relationship, Immunologic
Leukocyte Count
Models, Biological*
Neoplasms / blood,  drug therapy
Neutropenia / blood,  chemically induced*
Tetrahydroisoquinolines / administration & dosage*,  pharmacokinetics
Reg. No./Substance:
0/Antineoplastic Agents; 0/PM 00104; 0/Tetrahydroisoquinolines

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Co-culture with mesenchymal stem cells enhances metabolic functions of liver cells in bioartificial ...
Next Document:  Contrast-enhanced ultrasound of hepatocellular carcinoma: correlation between enhancement pattern an...